SCHEMBL1306459

SCHEMBL1306459

COCCNCC(=CCCCCC(=O)NO)COc1cccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 7/20 0.44
▸ HDAC6 Q9UBN7 6/20 0.44
▸ HDAC2 Q92769 5/20 0.44
▸ HDAC3 O15379 4/20 0.44
▸ HDAC4 P56524 4/20 0.44
▸ HDAC7 Q8WUI4 4/20 0.44
▸ HDAC10 Q969S8 4/20 0.44
▸ HDAC11 Q96DB2 4/20 0.44
▸ HDAC8 Q9BY41 4/20 0.44
▸ HDAC9 Q9UKV0 4/20 0.44
▸ HDAC5 Q9UQL6 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ OGG1 O15527 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ HTR1B P28222 3/20 0.41
▸ HTR1D P28221 1/20 0.40
▸ SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1306457 1.00 HDAC1 (0.44) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL1306454 1.00 HDAC1 (0.44) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL1306671 0.90 CNR2 (0.48) KDM4EALDH1A1HPGDTDP1OGG1
SCHEMBL1306274 0.90 KDM4E (0.50) KDM4EALDH1A1HPGDTDP1OGG1
SCHEMBL1306279 0.90 KDM4E (0.50) KDM4EALDH1A1HPGDTDP1OGG1
SCHEMBL1306674 0.90 CNR2 (0.48) KDM4EALDH1A1HPGDTDP1OGG1
SCHEMBL1306277 0.90 KDM4E (0.50) KDM4EALDH1A1HPGDTDP1OGG1
SCHEMBL1306201 0.87 HTR1B (0.45) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL1306198 0.87 HTR1B (0.45) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL1306204 0.87 HTR1B (0.45) HDAC1HDAC6HDAC2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP claimed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US claimed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US claimed
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP disclosed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US disclosed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US disclosed
EP-2089354-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Korea Research Institute Of Chemical Technology (KR) 2009-08-19 — — EP disclosed
WO-2008054154-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC6 10/4885HDAC2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback